SecBot SecBot
SECBOTREPLAY Home › Report › APGE

APGE · Apogee Therapeutics stockholders voted overwhelmingly to approve the…

Apogee Therapeutics, Inc. · 8-K filed Aug 11, 2026 at 16:00 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 11, 2026 at 16:00 ET

Apogee Therapeutics stockholders voted overwhelmingly to approve the $135.11/share all-cash acquisition by AbbVie, with 46,508,107 votes for and only 3,885 against, satisfying a key closing condition. The board also disclosed that all seven directors intend to resign effective at the merger's closing, a routine step in a change-of-control transaction. The non-binding advisory vote on executive merger-related compensation was rejected, but this does not affect deal consummation. The merger remains on track with German antitrust clearance already obtained and an Australian filing underway.

  • Stockholders approved the merger proposal with 46,508,107 votes for, 3,885 against, and 14,261 abstentions.
  • All seven directors (Michael Henderson, Mark C. McKenna, Lisa Bollinger, Jennifer Fox, William (BJ) Jones, Jr., Tomas Kiselak, Nimish Shah) intend to resign effective at the merger closing.
  • The non-binding advisory vote on executive merger compensation was not approved (19,323,605 for, 27,123,259 against), but this is not a condition to closing.
  • The merger is an all-cash acquisition by AbbVie at $135.11 per share, valuing Apogee at approximately $8.4B based on 62,140,183 voting shares outstanding.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access